Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Novo Nordisk (DE:NOVA)
FRANKFURT:NOVA
NOVA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€74.00 - €140.00
Previous CloseN/A
Volume1.40K
Average Volume (3M)1.82K
Market Cap
$369.52B
Enterprise Value€528.43B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)29.3
Beta0.51
Next Earnings
Feb 05, 2025EPS Estimate
0.8Last Dividend Ex-Date
Aug 16, 2024Dividend Yield1.24%
Share Statistics
EPS (TTM)2.85
Shares Outstanding3,390,128,000
10 Day Avg. Volume2,406
30 Day Avg. Volume1,819
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.31
Price to Cash Flow (P/CF)74.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€97.78Price Target Upside22.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Management And Growth PotentialAn abundance of additional catalysts are anticipated, all navigated by one of the most creative, disciplined management teams.
Market PositionNVO is well positioned in the growing diabetes and obesity market.
Stock Buyback ProgramThe 2024 share buyback program of DKK 20B is not impacted.
Bears Say
Financial PerformanceNovo guides to low single-digit negative operating profit growth impact in 2024 and mid-single digit impact in 2025, mostly associated with depreciation and amortization.
Operational ChallengesSupply constraints are expected to continue into 2025.
Strategic ConcernsInvestors are worried that LLY is ascendant while NVO and its rival both struggle to meet lofty expectations.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.60% Mutual Funds
0.09% Other Institutional Investors
98.22% Public Companies and Individual Investors
NOVA FAQ
What was Novo Nordisk’s price range in the past 12 months?
Novo Nordisk lowest stock price was €74.00 and its highest was €140.00 in the past 12 months.
What is Novo Nordisk’s market cap?
Novo Nordisk’s market cap is $369.52B.
When is Novo Nordisk’s upcoming earnings report date?
Novo Nordisk’s upcoming earnings report date is Feb 05, 2025 which is today.
How were Novo Nordisk’s earnings last quarter?
Novo Nordisk released its earnings results on Nov 06, 2024. The company reported €0.853 earnings per share for the quarter, beating the consensus estimate of €0.853 by <€0.001.
Is Novo Nordisk overvalued?
According to Wall Street analysts Novo Nordisk’s price is currently Undervalued.
Does Novo Nordisk pay dividends?
Novo Nordisk pays a Semiannually dividend of €0.362 which represents an annual dividend yield of 1.24%. See more information on Novo Nordisk dividends here
What is Novo Nordisk’s EPS estimate?
Novo Nordisk’s EPS estimate is 0.8.
How many shares outstanding does Novo Nordisk have?
Novo Nordisk has 3,390,128,000 shares outstanding.
What happened to Novo Nordisk’s price movement after its last earnings report?
Novo Nordisk reported an EPS of €0.853 in its last earnings report, beating expectations of €0.853. Following the earnings report the stock price went down -2.008%.
Which hedge fund is a major shareholder of Novo Nordisk?
Currently, no hedge funds are holding shares in DE:NOVA
---
Novo Nordisk Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€97.78 (22.22% Upside)
€97.78 (22.22% Upside)
Blogger Sentiment
Bullish
DE:NOVA Sentiment 86%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.73%
12-Months-Change
Fundamentals
Return on Equity
88.20%
Trailing 12-Months
Asset Growth
39.65%
Trailing 12-Months
Company Description
Novo Nordisk
Novo Nordisk A/S is a Denmark-based healthcare company, which manufactures and markets pharmaceutical products globally. The company operates through two segments, including Diabetes & Obesity Care, and Biopharmaceuticals. The company was founded in 1925.
---
NOVA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects strong financial performance and strategic growth in key areas such as GLP-1 treatments and obesity care, supported by significant R&D achievements. However, challenges remain with increased carbon emissions, supply constraints, and issues in the rare diseases segment. Despite these challenges, the positive developments in sales, profit, and R&D outcomes suggest more highlights than lowlights.Read More>---
NOVA Stock 12 Month Forecast
Average Price Target
€97.78
▲(22.22% Upside)
Technical Analysis
Best Analysts Covering NOVA
1 Year
1 Year Success Rate
8/22 ratings generated profit
1 Year Average Return
+1.04%
reiterated a buy rating 3 months ago
Copying Sachin Jain's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of +1.04% per trade.
---